Wolf–Hirschhorn (4p-) syndrome with West syndrome  by Motoi, Hirotaka et al.
Epilepsy & Behavior Case Reports 6 (2016) 39–41
Contents lists available at ScienceDirect
Epilepsy & Behavior Case Reports
j ourna l homepage: www.e lsev ie r .com/ locate /ebcrCase ReportWolf–Hirschhorn (4p-) syndrome with West syndromeHirotaka Motoi a,⁎, Tohru Okanishi a, Sotaro Kanai a, Takuya Yokota a, Tomohiro Yamazoe b,
Mitsuyo Nishimura c, Ayataka Fujimoto b, Takamichi Yamamoto b, Hideo Enoki a
a Department of Child Neurology, Comprehensive Epilepsy Center, Seirei-Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan
b Department of Epilepsy Surgery, Comprehensive Epilepsy Center, Seirei-Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan
c Laboratory of Neurophysiology, Seirei-Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan⁎ Corresponding author at: Department of Child Neur
Center, Seirei-Hamamatsu General Hospital, 2-12-12, Su
430-8558, Japan.
E-mail address: yellow1979@hotmail.co.jp (H. Motoi)
http://dx.doi.org/10.1016/j.ebcr.2016.07.001
2213-3232/© 2016 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 15 June 2016
Received in revised form 9 July 2016
Accepted 9 July 2016
Available online 15 July 2016Wolf–Hirschhorn syndrome (WHS) is a chromosomedisorder (4p-syndrome)which is characterizedby craniofacial
features and epileptic seizures. Here, we report a case ofWHSwithWest syndrome, in whom the seizures were re-
fractory to several antiepileptic drugs but were responsive to the addition of lamotrigine. The patient had epileptic
spasms at age seven months. The interictal electroencephalogram was hypsarrhythmic. After adding lamotrigine,
seizures decreased remarkably, and spasms disappeared. We have identiﬁed and described the very rare case of a
girl with WHS who also developed West syndrome. In this case, adding lamotrigine to her medications effectively
treated the spasms.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Wolf–Hirschhorn syndrome (WHS) is a chromosomal disorder (4p-
syndrome) characterized by the resemblance of craniofacial features to
an ancient “Greekwarrior helmet”, growth delay, congenital hypotonia,
mental retardation, and epileptic seizures [1]. Several patients have
been diagnosed with WHS, but in whom a 4p16.3 microdeletion can
be detected only by molecular probes on apparently normal chromo-
somes [2]. As a result of overlapping deletion analysis, the area currently
regarded as theWHS critical region (WHSCR) is restricted to the 165-kb
interval on 4p16.3 [3]. Three different genes have been independently
described as candidates for inducing WHS. Of these, WHSC1 overlaps
the distal boundary of theWHSCR [4], whereasWHSC2 is entirelywithin
the WHSCR [3]. The third candidate gene, the WHSCR-ﬂanking leucine
zipper/EF-hand-containing transmembrane (LETM1) gene, is involved
in Ca2+ signaling; thus, it is considered an excellent candidate gene
for WHS and, in particular, for WHS-associated seizures [5,6].
Epilepsy is one of the major concerns for parents and professionals
caring for children with WHS. Seizures tend to occur in over 90% of
the patients, with onset within the ﬁrst 3 years of life and with a peak
incidence at around 6–12 months of age [7]. The seizure types are uni-
lateral clonic or tonic seizures evolving to bilateral convulsion, general-
ized tonic-clonic seizures, or atypical absences [1]. The epilepsy inWHSology, Comprehensive Epilepsy
miyoshi, Hamamatsu, Shizuoka
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. This is an open access article underis generallywell controlledwithmonotherapy such as phenobarbital for
tonic–clonic seizures and valproate or ethosuximide for absence sei-
zures [8]. Sodium bromide in the past has been effective for the preven-
tion of unilateral and generalized tonic–clonic seizures and status
epilepticus [9]. The electroclinical ﬁndings in epilepsy withWHS are di-
vided into two patterns. The ﬁrst pattern consists of anterior, posterior,
or diffuse high voltage, 2- to 3-Hz slow waves, on which notches or
spikes superimpose. This pattern is observed in both interictal and
ictal periods in the patientswith atypical absence ormyoclonic seizures.
The second pattern consists of bursts of posterior rapid, repetitive
spikes. There has been only one report of a case with WHS who devel-
opedWest syndrome [8], a triad of clinical signs including ﬂexor or ex-
tensor spasms, often involving the extremities and head/neck,
hypsarrhythmia on electroencephalogram (EEG), and subsequent or
concurrent cognitive delay.
Here, we report a case of WHS with West syndrome, in whom the
seizures were refractory to several antiepileptic drugs but were ﬁnally
responsive to the addition of lamotrigine.
2. Case report
A six-year-old girl who was the ﬁrst child of nonconsanguineous,
healthy parents was brought to the hospital. There were no familiar
histories of epilepsy or other neurological disorders. Her history included
severe intrauterine growth restriction. She was born at 36 weeks gesta-
tion with a birth weight of 1360 g (−3.5 standard deviations (SD)), a
body length of 39.0 cm (−2.8 SD), and a head circumference of 27.3 cm
(−3.2 SD). Her Apgar score was 9 at 5 min. Abnormal craniofacialthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Diagnostic analyses. A: The G-banding test showed the patient to have a normal 46,
XX karyotype but a deletion of themost terminal portion of the short arm of chromosome
4. B: Fluorescence in situ hybridization (FISH) analysis identiﬁed a deletion of the 4p
subtelomere in chromosome 4p15.3. The Wolf–Hirschhorn syndrome (WHS) critical
region (WHSCR) is shown in red, and the control is shown in green.
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tures involvedher nosewithmicrognathia and low-set ears,were indicat-
ed. ShewasdiagnosedwithWHSafter aG-banding test identiﬁed that her
karyotype was a normal 46, XX, and there was a deletion of themost ter-
minal portion of the short arm of chromosome 4. Fluorescence in situ hy-
bridization (FISH) demonstrated a deletion of the 4p subtelomere,
speciﬁcally in chromosome 4p15.3 (Fig. 1). Echocardiography revealed
an atrial septal defect and pulmonary artery stenosis. At 2 months of
age, she presented with clonic seizures involving her right arm. The
interictal EEG showed spikes, sharp waves, and sharp & slow waves at
multiple foci. Magnetic resonance imaging showed neither brain malfor-
mation or other structural abnormality.
Phenobarbital reduced the seizure frequency during early infancy. At
age seven months, the seizures evolved to epileptic spasms that were
refractory to valproate, clonazepam, and zonisamide. The interictal
EEG was hypsarrhythmic (Fig. 2A). Lamotrigine and levetiracetam
were able to temporarily reduce seizure frequency. Adrenocorticotropic
hormone therapy was avoided because of her cardiac anomalies. The
untreated epileptic spasms occurred about 50 times per day. Until ageFig. 2. Electroencephalographic (EEG) data. A: At age sevenmonths, the patient's interictal EEG
normal after lamotrigine polytherapy.4 years and 3 months, she was treated with clonazepam
(0.15 mg/kg/day), topiramate (13 mg/kg/day), and levetiracetam
(45 mg/kg/day). However, her epileptic seizures persisted. At age
4 years and 4 months, we once again tried adding lamotrigine to her
other antiseizure medications. After 3 months of lamotrigine
(1.0 mg/kg/day) polytherapy, seizures decreased remarkably, and epi-
leptic spasms disappeared. At age 4 years and 6 months, the EEG dem-
onstrated epileptic discharges consisting of spikes or sharp waves
were no longer present (Fig. 2B). At the last follow-up, age 6 years and
3 months, the epileptic spasms had disappeared.
3. Discussion
To our knowledge, there had been only one patient with WHS who
also developed West syndrome [8]. In that previous case, epileptic
spasms appeared at age 6 months, and the patient's sleep EEG showed
a hypsarrhythmic pattern interrupted by electrodecremental activity
heralded by a spasm. Phenobarbital was transiently effective for the
focal seizures.
In the present case, FISH revealed partial deletions of the area distal
to 4p15.3 with a 4p subtelomeric probe. The proximal boundary of the
WHSCR was deﬁned by the identiﬁcation of two individuals with all 4
components of the core WHS phenotype and with deletions of 4p16.3
that include the proposed candidate genes LETM1,WHSC1, andWHSC2
[5]. However, it remains unclear whether the type and severity of sei-
zures in patients with WHS correlates with the deletion size.
The addition of lamotrigine was effective in stopping the epileptic
spasms in our patient when added to clonazepam, topiramate, and
levetiracetam. The most likely mechanism underlying lamotrigine
treatment is the inhibitionof voltage-gated sodiumchannels,which stabi-
lizes neuronal membranes and consequently modulates presynaptic
neurotransmitter-like release of excitatory amino acids. Lamotrigine in-
creases the concentration of Ca2+ through the activation of the phospho-
lipase C-1,4,5-trisphosphate receptor/ryanodine receptor pathways and
through calcium-/calmodulin-dependent protein kinase II activation in
the dorsal root ganglionic neurons. Lamotrigine has also been shown to
inhibit glutamate hyperexcitability by suppressing voltage-dependent
Na+ and Ca2+ channels [10]. Recently, the LETM1 gene was identiﬁed asdemonstrated a clear hypsarrhythmic pattern. B: At age four years, the EEG had returned to
41H. Motoi et al. / Epilepsy & Behavior Case Reports 6 (2016) 39–41critical for the appearance of epilepsy inWHS [7,8,11]. It encodes a puta-
tive Ca2+ binding protein that regulates Ca2+ signaling and homeostasis
[5]. In our patient, the addition of lamotrigine to her other antiseizure
drugsmight have reduced the epileptic spasms by increasing the concen-
tration of Ca2+.
In conclusion, we have identiﬁed and described the very rare case of
a girl with WHS who also developed West syndrome. In this case, the
addition of lamotrigine to her other antiseizure drugs effectively treated
the epileptic spasms.
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